The combined delivery of oxytocin and galantamine was observed to be more beneficial in suppressing Aβ and tau aggregation and restoring cognitive deficits in young AD rats than the application of just galantamine, due to increased inhibition of AChE, ERK1/2, GSK3β and caspase-3 [258]. The gene discussed is MAPK3; the disease is Alzheimer disease.